STOCK TITAN

Kyowa Kirin Co. Ltd. - KYKOY STOCK NEWS

Welcome to our dedicated news page for Kyowa Kirin Co. Ltd. (Ticker: KYKOY), a resource for investors and traders seeking the latest updates and insights on Kyowa Kirin Co. Ltd..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kyowa Kirin Co. Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kyowa Kirin Co. Ltd.'s position in the market.

Rhea-AI Summary
Professor Julia Scarisbrick presents interim findings from Kyowa Kirin's PROSPER study at the World Congress of Cutaneous Lymphomas, highlighting the impact of mogamulizumab on symptom burden and quality of life in CTCL patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Kyowa Kirin Co., announces pre-clinical data of tivozanib eye drop for neovascular age-related macular degeneration to be presented at ARVO Annual Meeting. The disease affects vision in older individuals, with nAMD causing significant central vision loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Kyowa Kirin Co., Ltd. announces post-hoc analysis data from the Phase 2b study of rocatinlimab for atopic dermatitis to be presented at AAD 2024. The study shows significant improvement in clinical responses in patients with moderate-to-severe atopic dermatitis by Week 2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Kyowa Kirin Co., Ltd. announces the presentation of disease education and Phase 2b study data on rocatinlimab for atopic dermatitis at the AAD 2024 Annual Meeting. Atopic dermatitis affects up to 10% of adults and 20% of children globally, creating a significant clinical burden. The need for effective therapeutic options remains high, with rocatinlimab showing promising results in improving clinical responses in patients with moderate-to-severe atopic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Kyowa Kirin Co., Ltd. (TSE: 4151) has initiated a Phase 2 clinical trial for their novel nano-crystalized tivozanib eye drops (KHK4951) to treat diabetic macular edema (DME). The trial aims to assess the efficacy and safety of KHK4951, a small-molecule VEGFR tyrosine kinase inhibitor, in 150 patients across the US, Japan, Australia, and South Korea. The company is optimistic about the potential of KHK4951 to provide a non-invasive treatment option for DME patients, addressing the limitations of current standard of care intravitreal injection drugs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kyowa Kirin, Inc. (TSE: 4151) presented HRQL findings from a post hoc analysis of the MAVORIC trial at the 65th annual American Society of Hematology meeting. The study focused on patients with mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). The analysis revealed that symptoms of advanced MF/SS significantly impacted HRQL across all domains, with factors such as age, gender, itching severity, and impaired function playing a role. These findings shed light on the burdens of living with CTCL and provide valuable insights for patient care planning.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Kyowa Kirin presents studies on the burden and progressive nature of X-linked hypophosphatemia at ASBMR annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
none
-
Rhea-AI Summary
Kyowa Kirin to present new research on XLH at ASBMR annual meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Kyowa Kirin to present post-hoc analysis data on rocatinlimab for atopic dermatitis at EADV Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Kyowa Kirin Co., Ltd. will present post-hoc analysis data on rocatinlimab at the EADV Congress 2023. Rocatinlimab shows improvement in lichenification, SCORAD, and DLQI in adults with moderate-to-severe atopic dermatitis. Positive results may lead to potential therapeutic options for a significant patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Kyowa Kirin Co. Ltd.

OTC:KYKOY

KYKOY Rankings

KYKOY Stock Data

10.64B
240.92M
Medicinal and Botanical Manufacturing
Manufacturing
Link
Japan
Chiyoda Ku